1. Treat to Target in Gout

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

3. Introduction

4. Recognition and Acute Management of Gout

5. 2012 ACR Gout Guidelines Indications for Pharmacologic Urate-Lowering Therapy*

6. 2012 ACR Gout Guidelines Current Recommendations for Urate-Lowering Therapy

7. Treat to Individualized Serum Urate Targets

8. 2012 ACR Gout Guidelines Allopurinol as First-Line Urate-Lowering Therapy

9. Urate-Lowering Therapy Febuxostat

10. Urate-Lowering Therapy Uricosuric Agents

11. Initiating Urate-Lowering Therapy Flare Risk Without Prophylactic Coverage

12. Anti-Inflammatory Prophylaxis for Gout Flares

13. Continuing to Manage Gout

14. Treating Gout Is It a Marathon or a Sprint?

15. Treating to Target Has Serum Urate Level Been Achieved?

16. Managing Patients Who Are Not Meeting Target Serum Urate Levels

17. New Fixed-Dose Combination Therapy Lesinurad + Allopurinol

18. Emerging Combination Therapy Lesinurad + Febuxostat

19. Closing Comments